Skip to main content
Journal cover image

Efficacy and safety of reduced-dose non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: a meta-analysis of randomized controlled trials.

Publication ,  Journal Article
Wang, K-L; Lopes, RD; Patel, MR; Büller, HR; Tan, DS-Y; Chiang, C-E; Giugliano, RP
Published in: Eur Heart J
May 14, 2019

AIMS: Non-vitamin K antagonist oral anticoagulants (NOACs) require dose reductions according to patient or clinical factors for patients with atrial fibrillation (AF). In this meta-analysis, we aimed to assess outcomes with reduced-dose NOACs when given as pre-specified in pivotal trials. METHODS AND RESULTS: Aggregated data abstracted from Phase III trials comparing NOACs with warfarin in patients with AF were assessed by treatment using risk ratios (RRs) and 95% confidence intervals (CIs) stratified by patient eligibility for NOAC dose reduction. Irrespective of treatments, annualized rates of stroke or systemic embolism and major bleeding were higher in patients eligible for reduced-dose NOACs than in those eligible for full-dose NOACs (2.70% vs. 1.60% and 4.35% vs. 2.87%, respectively). Effects of reduced-dose NOACs compared with warfarin in patients eligible for reduced-dose NOACs on stroke or systemic embolism [RR 0.84 (95% CI 0.69-1.03)] and on major bleeding [RR 0.70 (95% CI 0.50-0.97)] were consistent with those of full-dose NOACs relative to warfarin in those eligible for full-dose NOACs [RR 0.86 (95% CI 0.77-0.96) for stroke or systemic embolism and RR 0.87 (95% CI 0.70-1.08) for major bleeding; interaction P, 0.89 and 0.26, respectively]. In addition, NOACs were associated with reduced risks of haemorrhagic stroke, intracranial haemorrhage, fatal bleeding, and death regardless of patient eligibility for NOAC dose reduction (interaction P > 0.05 for each). CONCLUSIONS: Patients eligible for reduced-dose NOACs were at elevated risk of thromboembolic and haemorrhagic complications when treated with anticoagulants. NOACs, when appropriately dose-adjusted, had an improved benefit-harm profile compared with warfarin. Our findings highlight the importance of prescribing reduced-dose NOACs for indicated patient populations.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Eur Heart J

DOI

EISSN

1522-9645

Publication Date

May 14, 2019

Volume

40

Issue

19

Start / End Page

1492 / 1500

Location

England

Related Subject Headings

  • Warfarin
  • Thiazoles
  • Stroke
  • Rivaroxaban
  • Randomized Controlled Trials as Topic
  • Pyridones
  • Pyridines
  • Pyrazoles
  • Intracranial Hemorrhages
  • Humans
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Wang, K.-L., Lopes, R. D., Patel, M. R., Büller, H. R., Tan, D.-Y., Chiang, C.-E., & Giugliano, R. P. (2019). Efficacy and safety of reduced-dose non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: a meta-analysis of randomized controlled trials. Eur Heart J, 40(19), 1492–1500. https://doi.org/10.1093/eurheartj/ehy802
Wang, Kang-Ling, Renato D. Lopes, Manesh R. Patel, Harry R. Büller, Doreen Su-Yin Tan, Chern-En Chiang, and Robert P. Giugliano. “Efficacy and safety of reduced-dose non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: a meta-analysis of randomized controlled trials.Eur Heart J 40, no. 19 (May 14, 2019): 1492–1500. https://doi.org/10.1093/eurheartj/ehy802.
Wang K-L, Lopes RD, Patel MR, Büller HR, Tan DS-Y, Chiang C-E, et al. Efficacy and safety of reduced-dose non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: a meta-analysis of randomized controlled trials. Eur Heart J. 2019 May 14;40(19):1492–500.
Wang, Kang-Ling, et al. “Efficacy and safety of reduced-dose non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: a meta-analysis of randomized controlled trials.Eur Heart J, vol. 40, no. 19, May 2019, pp. 1492–500. Pubmed, doi:10.1093/eurheartj/ehy802.
Wang K-L, Lopes RD, Patel MR, Büller HR, Tan DS-Y, Chiang C-E, Giugliano RP. Efficacy and safety of reduced-dose non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: a meta-analysis of randomized controlled trials. Eur Heart J. 2019 May 14;40(19):1492–1500.
Journal cover image

Published In

Eur Heart J

DOI

EISSN

1522-9645

Publication Date

May 14, 2019

Volume

40

Issue

19

Start / End Page

1492 / 1500

Location

England

Related Subject Headings

  • Warfarin
  • Thiazoles
  • Stroke
  • Rivaroxaban
  • Randomized Controlled Trials as Topic
  • Pyridones
  • Pyridines
  • Pyrazoles
  • Intracranial Hemorrhages
  • Humans